S

Sanofi

Global pharma company; vaccines and R&D

PPM/Launch Leader

Full-TimeDeadline 12/6/26
No salary listed
Senior, Expert
Bachelor's, Master's, MBA
Shanghai, China
In Person
Operations & LogisticsSupply Chain Management

About the job

Requirements
  • Experience of 8–12 years in Supply Chain, with a strong focus on Demand Planning, product strategy, Integrated Business Planning, or Sales and Operations Planning in a multinational pharmaceutical or fast-moving consumer goods environment.
  • Experience in product leadership or end-to-end supply planning is highly preferred.
  • Experience leading executive-level business reviews and governance.
  • Deep understanding of China healthcare policy dynamics, including National Reimbursement Drug List events, Volume-Based Procurement, provincial tenders, and new product launch processes; familiarity with local manufacturing and China-for-China supply chains.
  • Proven track record leading or optimizing Integrated Business Planning or Sales and Operations Planning processes at market or regional level.
  • Proficiency in demand planning tools such as Kinaxis and SAP APO/IBP; experience with artificial intelligence or machine learning forecasting.
  • Ability to influence and coordinate across senior cross-functional stakeholders in China and at global level.
  • Written and verbal communication skills in Mandarin and English, and executive presentation skills.
  • Bachelor's degree or above in Supply Chain, Business, Engineering, or a related field.
Responsibilities
  • Coordinate and facilitate executive-level forums, including the Greater China Management Business Review and China SWAT meetings; prepare structured agendas, executive presentations, dashboards, and actionable follow-ups.
  • Serve as the central point of coordination between Manufacturing & Supply, Commercial, Finance, and GBU leadership for executive governance cadences.
  • Lead standardization and continuous optimization of the Integrated Business Planning process across Greater China in alignment with the global five-step framework: Product Management Review, Demand Review, Supply Review, Integrated Reconciliation, and Management Business Review.
  • Drive digital initiatives to improve Integrated Business Planning efficiency and key performance indicators, including forecast accuracy, forecast bias, mean absolute percentage error, order-to-cash, and inventory levels.
  • Promote adoption of artificial-intelligence-based forecasting tools and digital platforms in the Integrated Business Planning cycle.
  • Lead root-cause analysis and action plans to optimize significant deviations in demand-planning key performance indicators.
  • Establish and improve processes and controls, including knowledge capture and lessons learned, to manage China-market volume volatility driven by National Reimbursement Drug List listing or delisting events, Volume-Based Procurement tender cycles and outcomes, and new product launches.
  • Build and maintain a market-intelligence framework to anticipate policy changes, competitive dynamics, and market-access events that affect demand.
  • Develop scenario-planning capabilities and risk-mitigation playbooks for high-volatility events to support proactive supply-chain responses.
  • Develop product-launch insights and a strategy framework.
  • Standardize ways of working across Greater China business groups, including General Medicines, Specialty Care, Vaccines, and relevant Consumer Healthcare and Specialty Care franchises.
  • Build knowledge-sharing infrastructure to capture best practices, lessons learned, and demand insights across business groups.
  • Build capabilities and upskill the demand-planning community in tools, processes, and methodologies.
  • Serve as a center of expertise for demand strategy and provide insights and recommendations to business-group supply-chain partners and local supply-chain heads.
  • Act as Product Leader for selected local-to-local business-development products, supporting the senior demand lead.
  • Lead China-market product launches, ensuring end-to-end supply readiness from demand planning through manufacturing and distribution.
  • Oversee end-to-end supply planning for local-to-local products, including setting portfolio vision and supply strategy, optimizing inventory policy and stock-coverage targets, coordinating with Engineering & Manufacturing Services, Sanofi manufacturing sites, and product planners, managing supply constraints and communicating hard constraints, and aligning local commercial plans with supply capabilities.
  • Serve as the main point of contact between Greater China market teams and local manufacturing platforms for assigned products.
  • Lead the Integrated Business Planning process for assigned products.
Desired Qualifications
  • Experience in product leadership or end-to-end supply planning is highly preferred.
  • MBA or an advanced degree.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Professional Development Budget
  • Parental Leave

Company News

Yahoo Finance
Oct 30th, 2026
Sanofi shares jump 6% as it raises 2026 outlook and signals appetite for bigger deals

Sanofi shares jumped nearly 6% on Friday after the drugmaker raised its 2026 outlook and said it is open to larger deals. The company now expects sales to grow in the low teens this year, with business earnings per share up in the mid-teens at constant exchange rates. Third-quarter sales rose 14.3% to 14.44 billion, and operating income was 5.43 billion. Dupixent remained the main growth driver, with sales up 34.8% to 5.7 billion. New medicines added 1.4 billion. Chief financial officer Francois Roger said Sanofi could consider deals above its typical $2 billion to $5 billion range. The company continues to focus on immunology, rare diseases, and vaccines.

Yahoo Finance
Oct 30th, 2026
Sanofi lifts 2026 guidance as Q3 sales rise 14.3% to $15.6B on Dupixent strength

Sanofi reported third-quarter sales of €14.4 billion, up 14.3% at constant exchange rates, and raised its 2026 outlook. Business operating income rose 19.7%, while business EPS increased 19.6%. The company now expects 2026 sales growth of 13% to 15% and business EPS growth of 15% to 17%. Dupixent sales hit €5.7 billion, with more than 1.5 million patients treated worldwide. Sanofi still targets Dupixent sales of €25 billion by 2030. Sanofi is focusing on immunology, rare diseases, and vaccines. It discontinued two development programmes and expanded its Regeneron alliance to four next-generation antibodies. Planned divestments are expected to cut 2027 sales by about €1.3 billion.

Yahoo Finance
Oct 30th, 2026
Sanofi raises 2026 guidance after Q3 sales rise 14.3% to $15.6B, with Dupixent up 34.8%

Sanofi raised its 2026 guidance after third-quarter sales grew 14.3% at constant exchange rates (CER) to €14,444 million. Business earnings per share (EPS) rose 19.6% at CER to €3.55. The company now expects full-year sales to grow by a low-teens percentage at CER, and business EPS by a mid-teens percentage. Dupixent sales rose 34.8% to €5.7 billion. Sales of newly launched drugs, including ALTUVIIIO, Ayvakit, and Rezurock, climbed 31.4% to €1.4 billion. Vaccines sales fell 6.6% to €3.2 billion. Selling and general expenses fell 0.9% to €2.3 billion. Research and development spending was broadly stable at €1.8 billion. Chief executive officer Belén Garijo said the company's priority is to protect earnings when Dupixent loses exclusivity.

PR Newswire
Oct 29th, 2026
Novavax earns $125M milestone as Sanofi starts Phase 3 flu-COVID vaccine trial

Novavax has earned a $125 million milestone payment after Sanofi dosed the fifth patient in a Phase 3 trial of an influenza-COVID-19 combination vaccine in Europe. The trial tests the safety and immune response of Novavax's COVID-19 vaccine, Nuvaxovid, combined with Sanofi's Efluelda/Fluzone High-Dose flu vaccine in adults aged 60 and older. Novavax could receive a $75 million milestone once manufacturing technology transfer is completed, expected in mid-2027. It is also eligible for $225 million upon a US launch of a combination vaccine, plus royalties on Sanofi sales. "To date, the partnership has generated over $1 billion in revenue for Novavax," said chief executive officer John C. Jacobs.

Yahoo Finance
Oct 29th, 2026
Sanofi brings non-mRNA COVID-19 vaccine Nuvaxovid to 10 provinces and Yukon for 2026-2027

Sanofi Canada said its protein-based, non-mRNA COVID-19 vaccine, Nuvaxovid, will be available in all 10 provinces and the Yukon for the 2026-2027 respiratory season. It will be offered through provincial respiratory programs and most private insurers. The vaccine is already available in British Columbia, Alberta, and Quebec. In Ontario, it should reach healthcare provider offices and public health units from the week of October 26, 2026, with pharmacies to follow. Nuvaxovid is approved for people aged 12 and older. Sanofi says pivotal phase 3 trials showed about 90% efficacy against symptomatic COVID-19. Nearly 77% of Canadian adults skipped a COVID-19 vaccine last season, according to the company. Sanofi hopes more choice will encourage uptake.